XML 20 R9.htm IDEA: XBRL DOCUMENT

Segment Reporting

12 Months Ended

Jun. 30, 2023

NOTE 4. SEGMENT REPORTING

Identification of reportable operating segments

Operating segments are reported in a manner consistent with internal reports which are reviewed and used by Management and the Board of Directors (who are identified as the Chief Operating Decision Makers (‘CODM’)). The Group operates in one operating segment, being Cancer Immunotherapy.


Operating segment information June 30, 2023	Immunotherapy A$			Unallocated A$		Consolidated A$
Revenue
License revenue		—			—		—
Other income
Research material sales		191,721			—		191,721
Grant income		3,314,001			—		3,314,001
Net gain on fair value movement of warrants					131,896		131,896
Net gain on foreign exchange					623,511		623,511
Interest income					938,999		938,999

Total revenue and other income		3,505,722			1,694,406		5,200,128

Result
Segment Result		(41,431,305	)		1,534,957		(39,896,348	)

Profit/(loss) before income tax expense		(41,431,305	)		1,534,957		(39,896,348	)

Income tax expense		—			—		—

Loss after income tax expense							(39,896,348	)
Total segment assets		147,448,990			—		147,448,990
Total segment liabilities		10,979,601			—		10,979,601


Operating segment information June 30, 202 2	Immunotherapy A$			Unallocated A$		Consolidated A$
Revenue
License revenue		170,369			—		170,369
Other income
Research material sales		84,018			—		84,018
Grant income		4,459,974			—		4,459,974
Net gain on fair value movement of warrants		—			591,070		591,070
Net gain on foreign exchange		—			1,228,122		1,228,122
Interest income		—			224,520		224,520

Total revenue and other income		4,714,361			2,043,712		6,758,073

Result
Segment Result		(33,929,768	)		1,718,976		(32,210,792	)

Profit/(loss) before income tax expense		(33,929,768	)		1,718,976		(32,210,792	)
Income tax expense							(34	)

Loss after income tax expense							(32,210,826	)

Total segment assets		102,169,550			—		102,169,550
Total segment liabilities		8,092,184			—		8,092,184


Operating segment information June 30, 2021	Immunotherapy A$			Unallocated A$			Consolidated A$
Revenue
License revenue		—			—			—
Other income
Research material sales		312,841			—			312,841
Grant income		3,549,965			—			3,549,965
Net gain on fair value movement of warrants		—			—			—
Net gain on foreign exchange		—			—			—
Interest income		—			105,327			105,327

Total revenue and other income		3,862,806			105,327			3,968,133

Segment Result		(19,665,904	)		(10,236,687	)		(29,902,591	)

Profit/(loss) before income tax expense		(19,665,904	)		(10,236,687	)		(29,902,591	)
Income tax expense								(33	)

Loss after income tax expense								(29,902,624	)

Total segment assets		82,030,533			—			82,030,533
Total segment liabilities		8,758,922			—			8,758,922